Resistance of a Rodent Malaria Parasite to a Thymidylate Synthase Inhibitor Induces an Apoptotic Parasite Death and Imposes a Huge Cost of Fitness by Muregi, Francis W. et al.
Resistance of a Rodent Malaria Parasite to a Thymidylate
Synthase Inhibitor Induces an Apoptotic Parasite Death
and Imposes a Huge Cost of Fitness
Francis W. Muregi
1,2*, Isao Ohta
3, Uchijima Masato
1, Hideto Kino
4, Akira Ishih
1
1Department of Infectious Diseases, Hamamatsu University School of Medicine, Hamamatsu, Japan, 2Centre for Biotechnology Research and Development, Kenya
Medical Research Institute (KEMRI), Nairobi, Kenya, 3Laboratory for Ultrastructure Research, Research Equipment Centre, Hamamatsu University School of Medicine,
Hamamatsu, Japan, 4Institute of Experimental Animals, Hamamatsu University School of Medicine, Hamamatsu, Japan
Abstract
Background: The greatest impediment to effective malaria control is drug resistance in Plasmodium falciparum, and thus
understanding how resistance impacts on the parasite’s fitness and pathogenicity may aid in malaria control strategy.
Methodology/Principal Findings: To generate resistance, P. berghei NK65 was subjected to 5-fluoroorotate (FOA, an
inhibitor of thymidylate synthase, TS) pressure in mice. After 15 generations of drug pressure, the 2% DT (the delay time for
proliferation of parasites to 2% parasitaemia, relative to untreated wild-type controls) reduced from 8 days to 4, equalling
the controls. Drug sensitivity studies confirmed that FOA-resistance was stable. During serial passaging in the absence of
drug, resistant parasite maintained low growth rates (parasitaemia, 15.5%62.9, 7 dpi) relative to the wild-type (45.6%68.4),
translating into resistance cost of fitness of 66.0%. The resistant parasite showed an apoptosis-like death, as confirmed by
light and transmission electron microscopy and corroborated by oligonucleosomal DNA fragmentation.
Conclusions/Significance: The resistant parasite was less fit than the wild-type, which implies that in the absence of drug
pressure in the field, the wild-type alleles may expand and allow drugs withdrawn due to resistance to be reintroduced. FOA
resistance led to depleted dTTP pools, causing thymineless parasite death via apoptosis. This supports the tenet that
unicellular eukaryotes, like metazoans, also undergo apoptosis. This is the first report where resistance to a chemical
stimulus and not the stimulus itself is shown to induce apoptosis in a unicellular parasite. This finding is relevant in cancer
therapy, since thymineless cell death induced by resistance to TS-inhibitors can further be optimized via inhibition of
pyrimidine salvage enzymes, thus providing a synergistic impact. We conclude that since apoptosis is a process that can be
pharmacologically modulated, the parasite’s apoptotic machinery may be exploited as a novel drug target in malaria and
other protozoan diseases of medical importance.
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Introduction
Malaria, caused by protozoan parasite of the genus Plasmodium is
the most widespread parasitic disease, with malaria endemic
regions encompassing approximately 40% of the global human
population. Traditionally, four Plasmodia species cause human
malaria, P. falciparum, P. vivax, P. ovale and P. malariae, but recently
the primate parasite P. knowlesi was established as the fifth
causative agent [1]. The global malaria situation is being
exacerbated by the fact that P. falciparum, which causes about
90% of all global malaria cases, has rendered most of the classical
antimalarials ineffective. More worrying are recent reports from
Southeast Asia region, specifically near the Thai-Cambodia
border indicating that resistance to the artemisinin-based combi-
nation therapies (ACTs), the only fully effective class of
antimalarial drugs against falciparum malaria, is imminent [2].
Whereas the rising incidence in malaria morbidity and mortality is
largely associated with drug failure following resistance, it is also
possible that resistance induces an alteration of the intrinsic
parasite traits that may influence parasite fitness (growth and
multiplication) and virulence (harm to the host following infection),
thus impacting on malaria mortality and morbidity [3,4]. Drug
pressure, the force that mainly drives antimalarial drug resistance
through a population is a function of antimalarial drug use [5,6].
While exposure of parasites to sub-curative drug doses facilitate
the evolution of ‘classical drug resistance’ (point mutations,
overexpression of target proteins), it can also engender genetical-
ly-encoded parasite traits that could influence parasite survival in a
drug environment [7].
There are very few reports on how development of resistance in
field populations of malaria parasites impacts on parasite fitness,
and indeed studies on the fitness of drug-resistance genes of
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parasite fitness and virulence owing to antimalarial drug resistance
should be investigated since understanding how resistance in the
field influences parasite fitness and pathogenicity can have a
bearing on development of effective malaria control strategies.
Unfortunately, this is extremely difficult to establish in the field
especially in malaria endemic regions due to various confounding
factors such as multiple clonal infections derived from separate
infective bites [9]. We thus used a rodent model of malaria to
generate resistance by exposing an isogenic strain of Plasmodium
berghei to sub-therapeutic levels of the antifolates pyrimethamine
(PYR) and 5-fluoroorotate (FOA) over several passages in mice.
PYR inhibits dihydrofolate reductase (DHFR), thus depriving the
parasite of essential folate cofactors. FOA is metabolized through
the action of orotate phosphoribosyltransferase into 5-fluoro-
orotidine 59-monophosphate (5F-OMP), which in turn is convert-
ed into 5-fluoro-uridylate (5F-UMP) aided by orotidylate decar-
boxylase. 5F-UMP is further activated into 5-fluoro-29-deoxyur-
idylate, known to be a potent inactivator of thymidylate synthase
(TS), the obligate source of dTTP for DNA synthesis in malaria
parasites since unlike the host cell, the parasite cell is unable to
salvage preformed pyrimidines. Orotic acid is the only preformed
pyrimidine that is utilized by malaria parasite, inspiring the belief
that analogues of this substrate such as FOA can be toxic to the
parasite [10,11]. Whereas TS and DHFR in bacteria and
metazoans occur as separate entities, that of malaria parasites
and other protozoans occur as a TS-DHFR bipeptide coded off a
single gene [12]. The bifunctional protein catalyzes formation of
deoxythymidylate (dTMP) from deoxyuridylate (dUMP) in the
thymidylate cycle using methelenetetrahydrofolate as a methylat-
ing agent. The dihydrofolate produced in this reaction is in turn
reduced through DHFR catalysis to tetrahydrofolate [13].
Inactivation of TS is thus thought to be the primary mechanism
through which FOA toxicity is mediated in malarial parasites. It
has also been reported that an additional mechanism of FOA’s
toxicity may involve incorporation of fluorinated antimetabolites
in form of 5-fluorouridine 59-triphosphate (5F-UTP) into the RNA
of malarial parasites [10].
In the present study, we observed that not only could a FOA-
resistance line be readily generated, but also this resistance is stable
and imposes a considerable loss of fitness to the resistant line.
During growth in absence of drug, the FOA-resistant parasite line,
but not the wild-type showed an apoptosis-like death. This
observation is interesting since to the best of our knowledge, it is
the first report where resistance to a chemical stimulus and not the
stimulus itself is shown to induce apoptosis in a protozoan parasite.
For a long time, apoptosis has been thought to be a preserve of
metazoans, but mounting evidence within the last two decades
demonstrating that programmed cell death (PCD) is also a feature
of unicellular organisms is increasingly causing a paradigm shift on
traditional tenets of PCD [14]. In metazoans, apoptosis represents
a programmed form of cell death that plays a distinctive role in
tissue development and homeostasis in response to an internal
physiological disturbance [15]. However, apoptosis in unicellular
organisms is thought to represent an altruistic behavior where a
part of population which is less competent or non-viable is
eliminated for the successful survival and onward transmission of
the more competent organisms [16,17]. So far, PCD has been
described in diverse protozoan parasites including Leishmania [18],
Trypanasoma [19], Giardia [20], in the ciliated protozoan Tetrahymena
thermophila [21], Entamoeba histolytica [22], Blastocystis hominis [23]
and Plasmodia [24–26]. PCD has also been reported in bacteria
[27], in yeast [28], in the slime mould Dictyostelium discoideum [29],
the dinoflagellate Peridinium gatunense [30], and in the euglenoid
Euglena gracilis [31]. We report that irrespective of FOA-resistance
mechanisms, the net biochemical effect in the aberrant parasite
was depleted dTTP levels and its subsequent thymineless death
through apoptosis.
Materials and Methods
Drugs, parasites and hosts, and ethics
Respective concentrations of 5-fluoroorotic acid hydrate (FOA)
(SigmaH, USA) and pyrimethamine (PYR) (SigmaH, USA) were
constituted by first solubilizing the compounds in dimethyl
sulfoxide (final concentration ,0.2%) and then dissolving in
distilled water. The solutions were stored at 4uC until use.
Plasmodium berghei (strain NK65), a rodent malaria parasite was
used for all the studies. The parasite, maintained in a frozen state
(280uC) at the Parasite Bank of the Department of Infectious
Diseases, Hamamatsu University School of Medicine was
inoculated intraperitoneally (ip) into a male outbred ICR mouse,
the donor mouse to the experimental mice. The day of infection
was denoted as day 0 post-infection (pi), and all experiments were
done using this revived parasite to ensure isogenicity of the
parasite. Five days after parasite inoculation (at day 5 pi), its
parasitaemia was assessed microscopically (Olympus BX50F4,
Olympus Optical Co., LTD., Japan) at 10006 magnification by
examining Giemsa-stained thin tail-vein blood smears, and its
erythrocyte density was determined using a haemocytometer (F-
520, Sysmex Corporation, Japan). The mouse was later sedated,
bled via cardiac puncture and blood collected in heparinized
tubes. The parasitaemia was adjusted downwards using physio-
logical saline and each of the experimental male ICR mouse, 7-
week old weighing about 30 g (Japan SLC Inc., Hamamatsu,
Japan) was inoculated ip with approximately 1610
5 parasitisized
erythrocytes in volumes of 0.2 ml [32]. The inoculated mice were
randomized into appropriate groups, housed in cages and
maintained in the animal facility on a commercial diet and water,
ad libitum. This work was fully approved by the Institute of
Experimental Animals, Hamamatsu University School of Medi-
cine (Approval Number: 2007087), in which facility the rodent
models of this study were maintained and all animal experiments
conducted, in accordance to the Institute’s Guide for the Care and Use
of Laboratory Animals. All mice that were either cured or were
deemed to have completed their intended use were euthanased in
the course of experiments.
Exerting drug selection pressure to generate resistance
The ‘2% Relapse Technique’ (2% RT) of Peters and Robinson
[33] was employed to exert drug selection pressure against P.
berghei NK65 in mice, aiming to generate resistance. In this
technique, a single dose of the test drug is administered to a group
of mice immediately after infection, while a second group is
infected but not treated to serve as a control. The drug dose is pre-
determined such that it causes a delay time of between 5 and 7
days for the treated group to reach a 2% parasitaemia level,
relative to the untreated controls. This delay time is termed as the
‘2% delay time’ (2% DT). The progress of infection is monitored
daily and a new passage followed by immediate treatment is done
on reaching the 2% DT. The acquisition of resistance is assessed
by progressive reduction in 2% DT [33,34]. In our study, 15 mice
infected with P. berghei NK65 parasite (1610
5) were divided into
three equal groups. The first two groups received oral doses (po) of
40 mg/kg bw. FOA and 30 mg/kg bw. PYR immediately after
infection, while the third group served as the untreated control.
We had earlier experimentally determined that these drug doses
could cause a 2% DT of at least 5 days relative to the untreated
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treatment was iterated over several generations while monitoring
reduction in 2% DT.
In vivo antimalarial assays to confirm resistance and its
stability
Drug sensitivity studies can help determine the level of
resistance of a generated ‘resistant line’ [33,34]. To confirm
resistance, the drug-exposed and the wild-type parasites were serial
passaged in the absence of drug, and in vivo drug sensitivity studies
undertaken at selected passages. For serial passaging, 6 mice per
group were inoculated with respective parasites (1610
5) at day 0 pi
and the parasitaemias of mice determined at day 7 pi, with one
mouse per group serving as the parasite donor for subsequent
passaging. Drug sensitivity studies were done at passages 2, 5, 10
and 12, where mice (in groups of 5) infected with respective
parasites were treated po twice a day for three consecutive days
starting from day 4 pi with either 6.67 mg/kg body weight (bw)
FOA (40 mg/kg cumulative dose) or 5 mg/kg bw PYR (30 mg/kg
cumulative dose). For each drug, at least two independent
experiments were conducted. Drug efficacy was measured by
percentage (%) parasitaemia suppression on day 7 pi after
observation of Giemsa-stained thin blood smears under micro-
scope, relative to the untreated controls; mice survival rate (%) and
longevity relative to the untreated controls; and drug curative
effect to mice (%). Mice that showed parasites on day 4 pi, but
were aparasitaemic on subsequent days post-treatment up to day
60 pi were considered cured [35]. Percentage (%) parasitaemia
suppression for the drugs was calculated as: 1002[(mean
parasitaemia treated/mean parasitaemia control)6100] [36].
Resistance cost of fitness
Growth and multiplication of a parasite can be used as a
measure of its fitness, and since the parasites of this study are all
isogenic (all were derived from the same wild-type) differing only
on their drug responses, their growth rates was used as a measure
of fitness [7,37,38]. Parasites growth rate between days 4 and 7 pi
in the course of serial passaging in the absence of drug was used to
assess the parasites proliferation rates for the FOA- and PYR-
exposed parasites relative to their wild-type counterpart, and thus
their fitness. The percentage loss of fitness of the mutant parasites
relative to the wild-type was expressed as: 1002[(mean parasit-
aemia mutant/mean parasitaemia wild-type)6100]. For compar-
ison of mean parasitaemias at different time points, parametric
tests (two-tailed Student’s t-test, one-way ANOVA) and non-
parametric tests (Mann-Whitney, Kruskal-Wallis) were done using
Microsoft ExcelH 2004 and SPSS Statistics 17.0, respectively, with
P,0.05 being considered significant.
Morphological assessment of apoptosis through light
and transmission electron microscopy
The morphologies of parasites previously subjected to selective
drug pressure in mice were compared with that of the wild-type
during their growth in the absence of drug through examination of
Giemsa-stained thin tail-vein blood smears made at days 4 and 7
pi under light microscope. Giemsa-stained images were captured
with a Live View Digital SLR Olympus E-620 camera (OlympusH
Imaging Corp., Japan). The methods of Totino et al. [39] and
Massimine et al. [40] were adapted for thin-section transmission
electron microscopy (TEM), albeit with minor variations. The
morphology of the FOA-resistant and the wild-type parasites were
compared during passaging in the absence of drug. At day 7 pi,
blood was collected in heparinized tubes as earlier described and
used immediately for TEM studies. Parasitized erythrocytes were
washed in phosphate buffered saline (PBS) and fixed with 2.0%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 1 h
at 4uC, washed three times in the same buffer and fixed with 1%
osmium tetroxide in 0.1 M cacodylate buffer for 1 h at room
temperature. The cells were then washed in buffer, dehydrated in
graded ethanol, and embedded in Epon. Ultrathin sections (50 to
60 nm thick) were cut using a Reichert ultramicrotome OmU3,
collected on copper grids, double-stained with 2% aqueous uranyl
acetate and lead citrate and observed in a JEM-1220 (JEOL Ltd.,
Japan) transmission electron microscope under 80 kV.
Extraction of genomic DNA for oligonucleosomal DNA
fragmentation analysis by polyacrylamide gel
electrophoresis
Genomic DNA was extracted using the methods described
previously [24,41], albeit with some variations. In brief, blood was
collected into heparinized tubes from mice infected with FOA-
resistant or wild-type parasites at day 7 pi. Onto centrifuge tubes
containing 4 ml Ficoll gradient solution (Ficoll-paqueTM PLUS),
2 ml of blood was gently layered at the top without mixing, and
centrifuged at 1500 rpm for 30 min to separate erythrocytes from
leukocytes, plasma and other constituents. The supernatant was
aspirated and the pellets containing the red blood cells (RBCs)
were washed with 16PBS and centrifuged at 1800 rpm for 5 min,
followed by aspiration of the supernatant. The pellets were
aliquoted into eppendorf tubes, and RBC lysis buffer (0.15 M
NH4Cl, 7 mM KHCO3, 1 mM EDTA) added in double volumes
of the RBCs, thoroughly mixed and left to stand at room
temperature for 10 min. The tubes were centrifuged at 8000 rpm
for 5 min, and the supernatant discarded. The process of RBC
lysis was repeated twice to ensure complete lysis. The pellets were
suspended in 200 ml of cell lysis buffer (50 mM Tris pH 8.0,
20 mM EDTA, 1% SDS, and 0.1 M NaCl) to lyse their
membranes, after which 20 ml of proteinase K (500 units/ml)
and 10 ml RNase A (1 mg/ml) were added followed by incubation
at 60uC in a thermomixer (at 300 rpm) for .1 h and cooled down
at room temperature. An equal volume of phenol (in TE:10 mM
Tris pH 8.0/1 mM EDTA, pH 8.0) was added to the tubes,
gently mixed for 30 min and centrifuged at 15000 rpm for
15 min. The supernatant (nucleic acids) was transferred into clean
eppendorf tubes and two new rounds of phenol protein extraction
undertaken. The supernatant was again put into new eppendorf
tubes and an equal volume of chloroform added, gently mixed for
5 min and centrifuged at 15000 rpm for 5 min. The supernatant
was transferred into new tubes, 1/10 volumes of 3 M sodium
acetate (pH 5.2) and 2.5 volumes of 99% ethanol were added to
precipitate the DNA, and centrifuged at 15000 rpm for 5 min and
ethanol aspirated. The DNA was washed with 70% ethanol,
centrifuged again at 15000 rpm for 5 min and ethanol aspirated.
The DNA was solubilized in 100 ml TE buffer and 2 ml RNase A
added, followed by incubation at 37uC for 1 h in a thermomixer.
The concentration of the DNA solution was determined by
measurement of its absorbance at 260 nm by spectrophotometer.
Total DNA (3 m) was mixed with 106BlueJuice gel loading buffer
and tracking dye and loaded onto 8% polyacrylamide gel and
electrophoresed in 16 TBE (Tris/Borate/EDTA) buffer for
between 1 and 1.5 h at constant voltage of 120 V (maximum
current 4 mA). The gel was then stained with ethidium bromide
(1 mg/ml in water) for 30 min, rinsed with water and illuminated
with ultraviolet light for examination and photography. Two
independent experiments were conducted for nucleosomal DNA
fragmentation analysis.
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FOA-resistance is readily generated in 100 asexual cycles
Figure 1 shows 2% DT of parasites subjected to FOA (40 mg/
kg) and PYR (30 mg/kg) pressure in mice over successive serial
passages, expressed as a percentage of 2% DT for passage-1. In 15
serial passages that lasted 92 days in presence of FOA, the 2% DT
decreased by 50% from 8 days to 4, the time it took the wild-type
parasite to achieve 2% parasitaemia in the absence of drug. The
asexual blood stage cycle of P. berghei takes 22 to 24 h [42], and
therefore FOA-resistance was generated in 92–100 parasite
asexual cycles. However, parasites subjected to PYR over 12
serial passages (93 days, 93–101 asexual cycles) showed no change
in 2% DT, which remained constant at 8 days.
In vivo antimalarial assays confirmed that FOA-resistance
was acquired, and that FOA-resistance is stable
After subjecting parasites to selective drug pressure, another
round of serial passaging in mice was initiated this time in the
absence of the drug. FOA-exposed parasites were serially passaged
for 12 generations that lasted over 72 days (72–79 cycles), while
PYR-exposed and wild-type parasite lines were passaged for 10
generations. At passages 2, 5, 10 and 12, respective parasites lines
were subjected to in vivo drug sensitivity studies with cumulative
doses of 40 mg/kg FOA and 30 mg/kg PYR, administered po
over 3 days from day 4 pi. Figure 2 shows the drug sensitivity
patterns for FOA-exposed parasites at passages 2, 5, 10 and 12.
Most of the untreated control mice infected with FOA-exposed,
PYR-exposed and wild-type parasite lines died by day 10 pi with
increasing parasitaemias. However, PYR-treated mice infected
with either the PYR-exposed or wild-type parasites showed similar
parasitaemia patterns at passages 2, 5 and 10, where no parasites
could be observed under the microscope at days 7 and 10 pi, with
recrudescent parasites appearing at day 14 pi (data not shown).
The parasitaemia pattern for PYR-exposed parasite line mirrored
that of the wild-type parasite (Figure 2). The observation that
PYR-exposed line assumed the patterns of its wild-type counter-
part is congruent with its unaltered 2% DT, confirming lack of
resistance. On the other hand, mice infected with FOA-exposed
parasite line and treated with FOA showed similar parasitaemia
patterns (P.0.05) at passages 2, 5, 10 and 12, in which only a
slight non-significant (P.0.05) decline in parasitaemia at day 7 pi
was observed relative to day 4 pi, followed by gradual increase in
parasitaemia. Comparison of parasitaemias at days 4 (before start
of FOA treatment), 7, 10 and 14 pi across the four drug assays
showed no statistical difference (P.0.05). This data is consistent
with change in 2% DT for FOA-exposed parasite line and
confirms that FOA-resistance was acquired, and that the resistance
was stable. The stability of FOA resistance phenotype after a
period of dormancy was also investigated. FOA-resistant parasites
cryopreserved (280uC) immediately after generation of resistance
and stored for .1 year was revived in mice and assessed for
resistance stability using in vivo antimalarial assays as described
earlier. Parasitaemia patterns obtained after po treatment of mice
infected with 10
5 parasites with a cumulative dose of 40 mg/kg
FOA over three days assumed the parasiatemia patterns of FOA-
resistant line shown in Figure 2, indicating that resistance was not
lost with dormancy (data not shown).
FOA-resistance imposes a fitness cost to the parasite
Comparison of parasitaemias at days 4 and 7 pi among the
three parasites lines (FOA-resistant, PYR-exposed and wild-type)
grown in mice over 10–12 passages in the absence of drug
(Figure 3) revealed that altered intrinsic parasite properties influence its
Figure 1. Generation of resistance using ‘2%-Relapse Technique’ (2% RT). In 12 serial passages lasting a total of 93 days, pyrimethamine-
exposed parasite maintained a 2% DT of 8/9 days. In 15 serial passages, 5-Fluoroorotate parasite line (92 days) reduced its 2% DT from 8 days to 4,
equalling the 2% DT for the wild-type parasite.
doi:10.1371/journal.pone.0021251.g001
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difference in parasitaemias at day 4 pi for each passage (P.0.05).
However, at day 7 pi, there were clear and distinct patterns for
each parasite line. The FOA-resistant line showed significantly low
(P,0.05) growth rates over the 12 passages (mean parasitaemia
15.5%62.9) relative to the wild-type parasite (45.6%68.4). These
differences in parasitaemias translate into a three-fold faster
growth rate for the wild-type parasite, and an overall resistance
cost of fitness of 66.0% for the FOA-resistant line. Interestingly, for
the first three serial passages, the PYR-exposed parasite line had
significantly higher parasitaemias than the wild-type parasite
(P,0.05). Its mean parasitaemia of 59.7%66.5 at passage-2 was
approximately double that of the wild type (32.867.0%),
indicating a two-fold faster growth rate than the latter. At passage
4 (after 26 days, 26 asexual cycles) the parasitaemia descended to
the levels of the wild type, and maintained a similar (P.0.05)
growth pattern for the subsequent passages. This implies that
although a PYR-resistant phenotype could not be realized, the
sustained PYR pressure had either altered the parasite genotyp-
ically or the parasite had acquired other intrinsic traits so as to
cope with the new environment of drug pressure. Longevity of
survival can also be used as an indicator of the harm a given
parasite line imposes on the host. It was observed that mouse
infected with the FOA-resistant parasite had slightly longer
survival (12.063.5 days) which was statistically significant relative
to the wild-type (P, 0.001) and PYR-exposed lines (P, 0.005) with
survival of 8.960.7 and 9.360.8 days, respectively.
Light and transmission electron microscopy reveals
that resistance induces an apoptosis-like death in
FOA-resistant parasite
The morphologies of FOA-resistant and the wild-type parasites
grown in the absence of drug in the course of serial passaging in
mice were compared by light microscopic observation of thin
blood smears. The FOA-resistant line showed abnormal parasites,
the ‘crisis forms’ with decreased cytoplasmic volume and cell
shrinkage, assumed to be parasites committed to death process.
Other forms appeared as condensed bodies with darkly stained
chromatin dots, assumed to be due to chromatin condensation, the
classical morphological hallmark of apoptosis. As depicted in
Figure 4 (A and B), the aberrant FOA-resistant parasite forms were
observed in both the early and late phases of serial passaging. In
contrast, the wild-type parasites showed normal ellipsoidal
morphologies with normal chromatin dots and full cytoplasm
(Figure 4C). To further confirm the apoptosis-like phenomenon
observed in light microscopy, we conducted an ultrastructural
Figure 2. Parasitaemia patterns of mice infected with FOA-resistant parasite and orally treated with FOA. The mice were treated twice
daily for 3 days with FOA (40 mg/kg cumulative dose) at passages 2, 5, 10 and 12. Note that the patterns mirror each other, confirming that the
acquired FOA-resistance is stable. The discontinuous curve indicates that following FOA administration to mice infected with the wild-type parasite,
no parasites could be observed under the microscope until day 14 p.i when recrudescent parasites were observed.
doi:10.1371/journal.pone.0021251.g002
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through TEM. During the early stage of parasite development (the
ring forms and early trophozoites), there were no overt
morphological differences between the wild-type and the FOA-
resistant parasites that could set them apart. However, from
mature to late trophozoites leading to schizonts, the FOA-resistant
parasites showed pronounced structural differences from the wild-
type line (Figure 5, A & B). The wild-type parasite retained its
ultrastructural integrity with the nucleus, mitochondrion, digestive
food vacuole and intraparasitic vacuoles showing well-defined
morphologies. Furthermore, various membranes including the
nuclear membrane and the parasitophorous vacuolar membrane
fused with parasite plasma membrane appeared intact (Figure 5B).
Figure 5A shows a markedly electron-lucent FOA-resistant
parasite at late schizont stage, with electron-dense segmenters
which appear to be non-viable. This TEM observation is
consistent with the light microscopy (Figure 4A) where trophozo-
ites and schizonts appear to be condensed.
Resistance to FOA induces internucleosomal DNA
fragmentation
DNA fragmentation was investigated using the genomic DNA
extracted from FOA-resistant and wild-type parasites grown in the
absence of drug. The DNA was subjected to polyacrylamide gel
electrophoresis, which gives higher resolution for small molecules.
In two independent experiments (Figure 6, A & B), we observed
laddering patterns with the FOA-resistant but not the wild-type
parasite, serving as clear evidence that apoptosis was a feature of
FOA-resistant parasites since internucleosomal degradation of
DNA is the biochemical hallmark of apoptosis. The sharpest DNA
band was observed at <200 bp.
Discussion
The impact of resistance on parasite fitness and disease severity
(virulence) is a poorly understood phenomenon, much less the
drug-specificity of these effects and thus warrants empirical
investigations. To further knowledge on these aspects, we
subjected a rodent malaria parasite to selective drug pressure
using FOA and PYR, two antimetabolites that have specific targets
and well-defined biochemical sequelae resulting from inhibition of
their target enzymes. FOA-resistance was not only readily
generated in <100 asexual cycles of exposure to FOA, but also
it was stable (maintained over sequential blood-stage passages) as
revealed by drug sensitivity studies (Figure 1 and 2). The stability
was further confirmed by the observation that long periods of
dormancy exceeding one year did not result in loss of resistance
(data not shown). FOA is reported to be metabolized to toxic 5-
fluoro-29-deoxyuridylate which is a strong inhibitor of TS, an
essential enzyme for the de novo synthesis of thymidylate and
subsequently DNA synthesis. Since TS is the rate-limiting enzyme
in the de novo pyrimidine biosynthesis, it serves as an excellent drug
target [43]. FOA was previously reported to have potent in vitro
antiplasmodial activity against P. falciparum, and to be curative in in
vivo rodent models of malaria [44,45].
Figure 3. Comparison of growth patterns in the absence of drug for wild-type, FOA-resistant and PYR-exposed parasites. The
parasiatemias were assessed at days 4 and 7 post infection (pi) in the course of serial passaging the respective parasite lines in mice for up to 12 serial
passages in the absence of drug. The mean parasiatemias for the three parasite lines were not different (P.0.05) at day 4 p.i. At day 7 p.i, the wild-
type parasite had 3 times faster growth rate than the FOA-resistant parasite. The PYR-exposed line showed .1.5-fold faster growth rates for the first
three generations than the wild-type (P,0.05, day 7 p.i). However, at passage 4 (26 asexual cycles) the parasitaemia descended, and maintained a
similar (P.0.05) growth pattern as that of the wild-type. Note that passage-2 is the first represented passage in the chart since the first passage
(passage-1) is excluded since it served as a revival passage of the parasite in the donor mice.
doi:10.1371/journal.pone.0021251.g003
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mediated include qualitative and/or quantitative aspects of the
drug target through mutation, deletion or amplification. Other
factors that limit the quantitative or temporal aspects of interaction
between the drug and its target such as limitation of intracellular
accumulation of the drug may also play a role in resistance [46]. In
the absence of drugs or substrates, the TS of the mammalian cells
binds to specific regions of its cognate mRNA prompting a direct
feedback inhibition of TS mRNA translation [47]. It has been
reported that similar translational control mechanism occurs in
Plasmodia where TS-DHFR specifically blocks its own synthesis by
binding to TS-DHFR mRNA [48]. It can therefore be expected
that an aberrant TS is unable to bind to its cognate mRNA leading
to overexpression of the TS enzyme, thus conferring resistance. If
that were the case in FOA resistance, it would be expected that
resistance due to overexpression of the TS domain of the TS-
DHFR would also result in cross-resistance to antifolate drugs that
target DHFR such as PYR, since DHFR domain would be
overexpressed too. However in our study, the FOA-resistant
parasite was equally susceptible to PYR (30 mg/kg) as the wild-
type parasite (data not shown), and therefore resistance due to
amplification of the ts-dhfr gene was ruled out. This is consistent
with the fact that gene amplification of ts-dhfr gene has not been
demonstrated in field isolates, and appears to play no role in
clinical resistance [49–52]. In one-step in vitro selection protocol,
Rathod et al. [53] were able to rapidly generate strong and
genetically stable FOA-resistance (in 25 days) of up to 400-fold
against P. falciparum. Also congruent with our study is the
observation that FOA-resistance did not result in cross-resistance
to the antifolate PYR. Events occurring upstream of TS like
altered activation of FOA to 5-fluoro-orotidylate or altered means
of transport of the drug may also contribute to FOA resistance.
However, transport of FOA into the parasite cell is via
tubovesicular membrane (TVM), which also transports a broad
range of amino acid and nucleosides [54–56]. Thus, resistance
through altered TVM would severely deprive the parasite of
essential nutrients, thus hindering it growth and ability to complete
normal cycle, a situation not observed in our study. In the light of
the fact that FOA’s primary target is the parasites TS [10], and
that resistance to ‘single target’ antimalarial drugs such as PYR
and atovaquone has consistently been shown to be mediated via
point mutations on the genes of their target proteins
[49,50,52,57,58], FOA resistance conferred by mutations is
therefore plausible. Unlike FOA, PYR pressure over a similar
period of time (<100 asexual cycles) did not yield PYR resistance,
as confirmed by drug sensitivity studies. This reinforces the already
known fact that the rate of drug resistance, even for drugs with
similar mode of action (both FOA and PYR are single-target
drugs) is drug-specific.
When both FOA- and PYR-exposed parasite lines were
subjected to several serial passages in the absence of the drug, it
was observed that the effect of drug-exposure impacted their
growth and multiplication capacities differently (Figure 3). The
wild-type parasites showed a 3-fold faster growth rates than the
FOA-resistant line over 12 serial passages, which translated to
about 66% resistance cost of fitness. Interestingly, although the
PYR-exposed line did not acquire the resistance phenotype, it
showed a two-fold faster growth rate than the wild-type parasite
during the first three serial passages, later assuming the latter’s
growth pattern which it retained for the subsequent serial passages.
This implies that although the PYR-exposed line did not acquire
the resistance phenotype and remained susceptible to PYR, either
it was genotypically altered through mutations or had acquired
other traits to enable it surmount the effects of drug pressure [7].
Resistance to antifolates is due to consecutive accumulation of
point mutations on their target enzymes, mutations which act
synergistically leading to drug failure [49]. In the case of PYR, the
ser108asn mutation is established as the first step to PYR
resistance, and initial mutations may not lead to quantifiable
resistance. It is thus possible that due to PYR pressure, the PYR-
exposed parasite acquired only the initial point mutations in its
journey to become resistant.
Studies from a variety of pathogens including different species of
bacteria, Toxoplasma gondii, and viruses indicate that mutations
associated with drug resistance confer a fitness cost, and there
seems to exist a general consensus that mutant forms of an
organism are likely to be less fit than their wild-type strains in the
absence of selection [59–68]. Whether or not drug-resistant
mutants will survive in the absence of the drug is of clinical
relevance because if the parasites harboring resistance genes are
less fit than their wild-type counterparts, they would be expected
to diminish in numbers relative to the sensitive forms in the
absence of drug pressure. In such a scenario, the drug that
generated the resistance could later be reintroduced for clinical
use. Both field and laboratory reports regarding fitness costs of
resistance in malaria parasites are controversial and ambivalent,
although available data are largely skewed towards loss of fitness of
the resistant mutants relative to the wild-type forms [69–84]. It has
been reported that following CQ withdrawal in Malawi in 1993
after pervasive failure rate of up to 80%, prevalence of CQ-
resistant pfcrt genotypes decreased from 85% (1992) to 13% (2000)
[71]. These findings were corroborated by Mita et al. [72] who
later established that this was due to expansion of the wild-type
pfcrt allele in P. falciparum populations in absence of CQ pressure,
rather than a back mutation of K76T to K76 [73]. Similar results
have been reported from some areas of Southeast Asia including
Hainan region of China, Thailand, and Vietnam following
cessation of use CQ or SP [74–76,79–81]. Hayward et al. [70]
Figure 4. The photomicrographs of FOA-resistant and wild-type parasites during serial passaging in the absence of drug. A and B
show FOA-resistant parasite at passages 2 and 12 respectively, with dark/condensed chromatin dot & cell shrinkage characterized by small and more
dense cytosol (red arrowheads), confirming that the death phenomenon was a persistent feature of the FOA-resistant parasite line. The wild-type
parasite (C) shows the typical ellipsoidal morphology and full cytoplasm.
doi:10.1371/journal.pone.0021251.g004
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falciparum strains harboring CQ-resistance pfmdr1 alleles incurred a
25% fitness cost during the intraerythrocytic stage of growth.
Light microscopic examination of FOA-resistant and the wild-
type parasites during serial passaging in the absence of drug
revealed that the former had shrinking parasites with cytoplasm
appearing condensed (more dense) (Figure 4, A and B) while the
latter retained full ellipsoidal shape and normal cytoplasm
(Figure 4C). It is noteworthy that FOA-resistant parasites
consistently showed this morphology through the 12 serial
passages undertaken. This observation was rendered further
credence through TEM, where ultrastructures of both the wild-
type and the FOA-resistant parasites were overtly different
(Figure 5, A and B). The FOA-resistant parasite showed electron
dense segmenters and merozoites possibly due to condensation of
cytoplasm and compaction of nuclear chromatin, but within an
intact plasmalemma (Figure 5A). In contrast, the wild-type parasite
showed normal intracytoplasmic structures with well-defined
membranes (Figure 5B). These observations are consistent with
morphological characteristics of apoptosis. The hallmark bio-
chemical feature of apoptosis is endonuclease-mediated DNA
fragmentation, where DNA is initially cleaved into 300 kbp
fragments and/or 50 kbp fragments [85,86]. This is commonly
(but not always) followed by further cleavage of DNA into
Figure 5. Electron micrographs of FOA-resistant and wild-type parasites grown in mice in the absence of drug. In (B), the trophozoite
of the wild-type parasite shows normal ultrastructural morphology with various compartments and organelles well defined by membranes that have
retained their integrity. In (A), late schizont of FOA-resistant parasite is seen with intact plasmalemma housing non-viable segmenters/merozoites
that appear as electron dense bodies probably due to compaction of nuclear chromatin and condensation of cytoplasm. (C) is an immuno-gold
electron micrograph adapted from Bhowmick et al. [114] showing a similar ‘syncytial’ cell from P. falciparum with viable merozoites. Note the distinct
nucleus of segmenters. Abbreviations: CN, condensed segmenter; E, erythrocyte; FV, food vacuole; IPV, intraparasitic vacuole; M, mitochodria; N,
nucleus; NM, nuclear membrane; PM, plasma membrane; PV, parasitophorous vacuole; PVM, parasitophorous vacuolar membrane; VL, vacuolization.
doi:10.1371/journal.pone.0021251.g005
Thymineless Death of FOA-Resistant P. Berghei
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21251oligonucleosomal-sized fragments due to double stranded cleavage
of DNA at linker regions between nucleosomes, forming fragments
of 180–200 bp and multimers thereof [15,87]. In two different
experiments, we observed cleaved DNA with a characteristic sharp
band at <200 bp (Figure 6, A and B). Morphologic characteristics
of cells undergoing apoptosis include cytoplasmic condensation,
cell-shrinkage, nuclear condensation, DNA fragmentation and
vacuolization, and preserved plasma membrane integrity with
decreasing permeability [88,14,23]. In the late stages of apoptotic
process, the dying cells fragment into smaller pieces known as
apoptotic bodies, which are rapidly phagocytosed before mem-
brane alterations can occur, and are subsequently degraded within
lysosomes [15,89].
How is apoptosis mediated in the FOA-resistant parasite cell?
TS has been exploited in cancer chemotherapy, and is a target of
fluoropyrimidines, as well as folate-based inhibitors including
TomudexH, PemetrexedH and NolatrexedH (Thymitaq) [44,90–
92]. The inhibition of TS results directly in depletion of dTMP
and thus dTTP, an essential precursor for DNA leading to an
accumulation of dUMP and thus dUTP. The dearth of dTTP in
the cell leads to misincorporation of dUTP into DNA during DNA
replication, prompting a DNA repair process involving dUTP
excision by uracil-DNA glycosylase that leads to DNA damage
and cell death, a phenomenon termed as thymineless cell death
[44,93,94]. Thus, the imbalance in dTTP/dUTP and DNA
damage can result in induction of downstream events leading to
apoptosis [90,95]. It is therefore plausible that a defective TS in
FOA resistant mutants elicits similar sequelae to ones caused by
chemical inhibition of the TS, leading to parasite death via
apoptosis.
HL-60 cells represent an accepted classical model for apoptosis
and thus using HL-60 as a standard [89,96], it was estimated that
the level of apoptosis observed in FOA-resistant parasites to be
,10%, apparently a low level of parasite death to adequately
account for observed huge fitness cost of 66%. However, the early
cellular events in apoptosis are accomplished quickly, with only a
few minutes elapsing between onset of the process and the
formation of a cluster of apoptotic bodies. The subsequent
digestion of the phagocytosed apoptotic bodies is also rapid and
completed in less than an hour that even when there is a large-
scale PCD, only few dead cells can be observed [85,97–99]. Thus,
it has been argued that due to rapidity of apoptotic events in vivo,
relatively small fraction of apoptotic cells observed represents a
considerable cumulative cell death [15,100,101]. Moreover, the
development of blood stages of P. berghei in rodent models is
asynchronous, and since nucleic acids syntheses in malaria parasite
largely occurs at the trophozoite stage, it can only be expected that
parasite cells will show varying degree of apoptosis depending on
their phase of growth [11,102–106]. Finally, it is possible that since
the asexual stage parasite largely resides in the erythrocyte with
which it has close interactions (eg. through TVM networks), the
death of a ‘housed’ parasite could spawn rapid eryptosis [107–109]
thus making it difficult to quantify apoptosis in blood stage
parasites.
To date, not more than three studies have demonstrated that
asexual stages of P. falciparum cultures undergo chemically induced
apoptosis. Picot et al. [24] were the first to demonstrate plasmodial
apoptosis after observing oligonucleosomal DNA fragmentation in
CQ-sensitive (3D7) P. falciparum cultures exposed to CQ. This was
corroborated by Deponte and Becker [110], and later by Meslin
and co-workers [25] who reported that P. falciparum cultures
exposed to various chemicals had typical features of apoptosis
including internucleosomal fragmentation and disruption of
mitochondrial membrane potential. It has also been reported that
sexual stages of malaria parasite also undergo apoptosis during
sporogonic development in the mosquito vector as a means of
regulating parasite density. Al-Olayan et al. [26] observed that
during development in the Anopheles stephansi midgut, P. berghei
exhibited features of typical apoptosis found in metazoans
including chromatin condensation, DNA fragmentation and
externalization of phosphotidylserine to the outer lamellae of the
cell membrane. Interestingly, all the apoptotic features were
replicated in vitro, an indication that apoptosis plays a pivotal role
in controlling sporogony [26]. In the present study, we
demonstrate for the first time that in vivo, blood stage asexual
forms of malaria parasites can undergo drug resistance-induced
Figure 6. Resistance induces internucleosomal DNA fragmentation in FOA-resistant parasite grown in mice without drug.
Polyacrylamide gel electrophoretic fraction of DNA was done in two independent experiments, A and B. In A, lanes 1 represent DNA extracted from
the wild-type parasite that shows no cleavage, while lanes 2 represent cleaved DNA of FOA-resistant parasite, with the main band at <200 bp. Similar
results are represented in B, where the wild-type shows no cleaved DNA (lanes 1), while FOA-resistant parasite shows cleaved DNA and a clear band
at <200 bp (lanes 2). Lane M is the molecular size marker (pSG5/Hinf I and wX174/HincII for A, and pSG5/Hinf I for B).
doi:10.1371/journal.pone.0021251.g006
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executioners of apoptosis in metazoans—there is now mounting
evidence that members of cysteine peptidases clan CD may be
functionally homologous to metazoan caspases and could be
involved in a less regulated form of apoptosis in single-celled
eukaryotes [111]. Genes encoding two cysteine proteases, the
metacaspase-like proteins, PF14_0363 and PF13_0289 were
identified from the Plasmodium genome database although their
function in mediating apoptosis remains to be characterized
[25,112].
It is apparent that protozoan parasites have evolved effectors
and regulators of PCD different from that of multicellular
organisms, suggesting that the process of cell suicide in unicellular
organisms may be harnessed as a therapeutic strategy to selectively
activate PCD in the parasites [16]. Apoptotic machinery can be
stimulated or inhibited using either internal or external stimuli
including drugs. Therefore, a greater understanding of the effector
and regulatory mechanisms of PCD in malaria and other
protozoan parasites should be pursued to aid in rational design
and development of novel selective therapeutics targeted to the
specific biomolecules of the parasite. Encouragingly, this has a
precedent in cancer therapy, since anticancer agents are known to
mediate their activity through apoptosis [113]. To the best of our
knowledge, this is the first in vivo report to show that resistance to a
chemical (drug) other than the drug itself can induce apoptosis in
malaria parasite. Today, there is no reliable system to reproducibly
study PCD in malaria. We thus offer FOA-resistant parasite as a
biological tool to help validate and understand the molecular basis
underlying apoptosis not only in malaria parasites, but also in
other protozoan parasites of medical importance. Several
anticancer agents target TS and mechanism of resistance to TS
antimetabolites as well as the subsequent biochemical sequelae
may be similar to that of FOA-resistant malaria parasites. If this
can be demonstrated to be true, then our findings have potential to
be exploited in cancer therapy where apoptosis of TS inhibitor-
resistant tumour cells can be optimized by chemotherapeutically
targeting pyrimidine salvage enzymes such as thymidine kinase,
thus providing a synergistic impact. We conclude that since
apoptosis is a process that can be pharmacologically regulated, the
malaria parasite’s apoptotic machinery may itself be exploited as a
novel drug target and/or could aid in identifying new targets for
therapeutic intervention.
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